Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 25;14:1170759. doi: 10.3389/fimmu.2023.1170759

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Seidel, Hoffmann, Jahrsdörfer, Körper, Ludwig, Vieweg, Albers, von Maltitz, Müller, Lotfi, Wuchter, Klüter, Kirchhoff, Schmidt, Münch and Schrezenmeier

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Correlation between anti-S antibody concentrations and NT50 against B.1, BA.1, BA.2, and BA.5. (A) Correlation between anti-S antibody concentrations measured by anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and NT50 against B.1 (Spearman correlation 0.78). (B) Correlation between anti-S antibody concentrations measured by Elecsys Anti-SARS-CoV-2 S and NT50 against B.1 (Spearman correlation 0.79). (C) Correlation between anti-S antibody concentrations measured by anti-SARS-CoV-2 QuantiVac-ELISA (IgG) and NT50 against BA.1 (Spearman correlation 0.66). (D) Correlation between anti-S antibody concentrations measured by Elecsys Anti-SARS-CoV-2 S and NT50 against BA.1 (Spearman correlation 0.77). (E) Correlation between anti-S antibody concentrations measured by anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and NT50 against BA.2 (Spearman correlation 0.70). (F) Correlation between anti-S antibody concentrations measured by Elecsys Anti-SARS-CoV-2 S and NT50 against BA.2 (Spearman correlation 0.78). (G) Correlation between anti-S antibody concentrations measured by anti-SARS-CoV-2 QuantiVac-ELISA (IgG) and NT50 against BA.5 (Spearman correlation 0.72). (H) Correlation between anti-S antibody concentrations measured by Elecsys Anti-SARS-CoV-2 S and NT50 against BA.5 (Spearman correlation 0.76). Figures (A–H) Results of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as filled circles. The vertical dashed line at 176 BAU/ml for the anti-SARS-CoV-2 QuantiVac and at 210 U/ml for the Elecsys anti-SARS-CoV-2 represents the threshold above which CCP is considered high-titer CCP according to the FDA’s recommendations for investigational CCP (30).